The NAGA Group AG: NAGA Announces NAGA Pay Launch
3.11.2021 12:15:00 EET | Business Wire | Press release
NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for trading, cryptocurrencies and payments NAGA.com, announces the launch of the revolutionary payment platform "NAGA Pay" with UK / European payments and VISA debit card.
The unique program from NAGA Pay combines an IBAN account, a VISA debit card, a brokerage account, copy trading and physical crypto wallets, the latter being subject to licensing.
The brand-new NAGA Pay app supports payments in the EEA and the UK, as well as a globally recognized VISA debit card that is accepted by over 140 million merchants worldwide. Users can make bank transfers and send funds to friends for free in the NAGA Pay app. In addition, NAGA Pay is integrated into the entire NAGA trading infrastructure.
Benjamin Bilski, CEO of NAGA says: "We worked hard to deliver the new functionalities and are excited about the possibilities NAGA Pay offers to our customers. Besides being able to make payments and send money, users can also invest with one tap in over 1,500 assets including straight equities for just EUR 0.99 per trade. In addition, users can copy other traders and get copied. As soon as the crypto offer is approved, our app will be by far the most complete payment solution on the European market."
Bilski adds: "With NAGA Pay, we are expanding our target group by hundreds of millions of users, diversify our income streams and have completely new ways of acquiring and retaining customers. NAGA Pay will become extremely relevant to our marketing mix."
Furthermore, NAGA plans to offer various payment sources at the point sale. With a simple selection in their app at the checkout, users can decide whether the card account or their investment portfolio should serve as a source of payment. In the latter case, they would sell assets they select in real time to fund the payment.
"For example, if I have a balance of EUR 50 on my card and EUR 500 in Apple shares, I can use the app to decide which source will be selected for my payment at the checkout. In addition, we will allow cryptocurrencies such as Bitcoin or Ethereum to be selected as a means of payment by means of real-time exchange in the future. This is subject to the licensing of our crypto division, which we are currently working on," adds Bilski.
NAGA Pay offers a fully digital account opening process and is offered as a standard or premium solution. The premium account has lower fees for withdrawals, premium customer support and higher limits on transactions.
"This version is just the start of our very own appstore for financial services. We will also expand into wealth management, saving plans and a strong loyalty offering for our active clients," concludes Bilski.
The app can now be downloaded from the Apple Appstore and Google Play Store. Further information on the entire NAGA Pay offer can be found at https://www.naga.com/pay
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical VISA card and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
|
Language: |
English |
|
Company: |
The NAGA Group AG |
|
Hohe Bleichen 12 |
|
|
20354 Hamburg |
|
|
Germany |
|
|
E-mail: |
|
|
Internet: |
|
|
ISIN: |
DE000A161NR7 |
|
WKN: |
A161NR |
|
Indices: |
Scale 30 |
|
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005536/en/
Contact information
Name: Benjamin Bilski
Tel: +49 (0)40 5247 79153
Email: ben@naga.com, ingo.janssen@ubj.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom